Mead Johnson to operate independently from Bristol-Myers

Bristol-Myers Squibb is divesting Mead Johnson Nutrition to concentrate on biopharmaceuticals. The deal allows Bristol-Myers' shareholders to "exchange some, none or all of their shares of Bristol-Myers Squibb common stock for shares of Mead Johnson common stock," the company said.

View Full Article in:

Chicago Tribune (tiered subscription model) · Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA